



Corporate Update

January 2016

<https://www.youtube.com/watch?v=YYDoG-u3Ew8>





Corporate Update

January 2016

<https://www.youtube.com/watch?v=YYDoG-u3Ew8>



Disclaimer

THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This presentation has been prepared by Rex Bionics plc (the “Company”) and is general background information about the Company’s activities at the date of this presentation. The information in this presentation is provided in summary form only, does not purport to be complete and may be changed.

Neither this presentation, nor the information contained in it constitutes or forms part of an admission document or a prospectus and does not form any part of (and should not be construed as constituting or forming any part of) an offer of, or invitation to apply for, securities nor shall this presentation or any part of it, or the fact of its distribution, form the basis of or be relied on in connection with any investment decision, contract or commitment whatsoever. This presentation should not be considered a recommendation by the Company or any of its respective directors, members, officers, employees, agents or advisers in relation to any purchase of the Company’s securities, including any purchase of or subscription for any ordinary shares in the capital of the Company. Accordingly, information and opinions contained in this presentation are being supplied to you solely for your information only.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, as such, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions.

In addition, some of the financial information set out in this presentation is based on certain important assumptions and adjustments and does not purport to represent what our results of operations are on an audited basis or actually will be in any future periods. Neither the Company nor any of its respective members, directors, officers, employees or advisers nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation. Nothing in this presentation should be construed as a profit forecast. All information, opinions and estimates contained in this presentation are given as of the date of the presentation and are subject to change without notice.

The information and opinions contained in the presentation may be restricted by law and is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Company accepts no liability for any such distribution or any result of such distribution.

Certain information contained in this document constitutes “forward-looking statement”, which can be identified by the use of terms such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue”, “target” or “believe” (or the negatives thereof) or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results or actual performance of the Company may differ materially from any opinions, forecasts or estimates reflected or contemplated in this presentation. All projections, estimations, forecasts, budgets and the like are illustrative exercises involving significant elements of judgment and analysis, which may or may not prove to be correct. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. As a result, investors should not rely on such forward-looking statements in making their investment decisions. No representation or warranty is made as to the achievement or reasonableness of and no reliance should be placed on such forward-looking statements.

Further, the development plans for the Company as at the date of this document also comprise forward-looking information including a mixture of targets, milestones and other planned project management steps. These plans are subject to periodic review, change and reprioritisation by reference to the development of the Company.

Rex Bionics At-a-Glance

- Medical Robotics
- Pioneering “**Robot-Assisted Physical Therapy***”
-for Spinal Cord Injury (500k wheel chair users in US and EU) at Clinic and At Home
-and other physical therapy applications (eg Stroke)
- Positioning as “Work-horse” robot against Exoskeleton companies. Balance and power provided by hands-free system, not patient
- Founded 2007 in New Zealand
- 38 employees, SG&A in London; R&D and manufacturing in New Zealand
 - Listings AIM (RXB) and OTCQX (RXRBY)
- Early in commercial launch phase



Experienced, focused Executive Team.....

Commercial Leadership

- **Crispin Simon**, Chief Executive Officer (ex Smith & Nephew, Rexam, McKinsey, NM Rothschild,)
And Biocompatibles product Line Exits: Cancer/\$220m, Contact Lenses/\$105m; Cardiology/\$250m
- **Peter Worrall**, Chief Financial Officer (ex Pharminox, Vernalis).
- **Tracey White**, General Manager, New Zealand Operations (ex Siemens Healthcare)
- **Debra Leeves**, International Sales & Marketing (ex Pfizer, GSK, Merck and GE)


Technology/Manufacturing Leadership

- **Duncan Clement**, Director of Engineering (ex Quantel)
- **Richard Little**, Founder/Consultant (ex BAE Systems)
- **Mike Orange**, Director of Manufacturing (ex Air New Zealand)

Non-Executive Board

- David Macfarlane, Bill Hunter MD, Jeremy Curnock-Cook, Victoria Provis, John Plimmer

Delivering Value



Market Snapshot – Potential \$5 Billion Global Therapy Opportunity

- 500 Neurological Rehabilitation Units in US and EU
- 600,000 people living with Spinal Cord Injury (SCI), using a wheel chair
- 1% REX penetration is a \$700 million opportunity¹
- ~30% patients hospitalized annually from SCI-related complications²
- ~25,000 new cases of SCI each year²
- 1,600,000 Strokes occur annually in the US and EU³
- Almost 3 million wheelchair users in the US⁴
- Powered wheel chair market is worth \$1.8billion

Sources:

1. Assumes 600,000 SCI wheel chair users x 1% x \$120,000
2. National Spinal Cord Injury Statistical Center (NSCISC) - Spinal Cord Injury – Facts & Figures at a Glance 2015
3. American Heart Association Heart Disease and Stroke Statistics At-A-Glance 2015
4. www.newdisability.com/wheelchairstatistics.htm

The Case for Standing, Walking....and Robots

Physical and mental benefits of exercise in the upright position.

- Less pain
- Fewer bladder & urinary tract complications
- Fewer spasms, better sleep
- Fewer pressure sores
- Greater sense of well-being and self-esteem

***Birch et al : Presentation to ANZ Spinal Cord Society: November 2015**

Robotic assisted-therapy has the potential to offer:

- More efficient training at a lower cost
- Accelerated recovery and improved rehabilitation outcomes

And

Rex does not require crutches for balancing and stability

***Contreras-Vidal and Grossman: Conf Proc IEEE Eng Med Biol Soc.2013**

RAPPER II Interim Analysis: Excellent Outcomes (n=20)

.....

Primary End-Point

Completion of <i>REXercises</i> ("Treatment Success")	95%
--	-----

Secondary End-Points

Completion of Transfer	100%
------------------------	------

Serious Adverse Events	0
------------------------	---


Treatment-Related Adverse Events	0
----------------------------------	---

Adverse Events	1
----------------	---

RAPPER II Interim Analysis : ...and excellent feedback (n=19)

Percent in
Agreement

I found it easy to transfer into the REX



I would like to see REX more accessible

....and physicians see the REX Potential

Comments

Level of Applicability

Stroke

- *“We would buy 2 or 3 of these for our rehab hospitals if it was applicable for stroke”* – Physical Medicine and Rehabilitation Physician
- *“This has a lot of application for stroke because you could use this to force patients to use their weaker side. If I bought it for stroke, then the neighboring hospitals would all have to buy it for stroke as well”* - Physical Medicine and Rehabilitation Physician

Potentially high; needs to be defined in this large but heterogeneous population

Traumatic Brain Injury

- *“Traumatic brain injury rehab could command a higher price tag, it could even be as high as \$200,000 - \$300,000”* - Physical Medicine and Rehabilitation Physician
- *“If you can show benefit in TBI every VA hospital would have one, it is the hottest topic and the VA has funding and a mandate to do more for wounded warriors”.—VA hospital Rehab Chief*

Potentially high, depends on overall profile of patient ability to participate

REX Targeting Two SCI Market Segments.....

REX – Designed for rehab centers & hospitals, rapidly adjustable for each user

REX
BIONICS

ROBOT ASSISTED PHYSIOTHERAPY



REX P – Custom fitted to each user enabling use at home and at work

REX
BIONICS

REX P ROBOT ASSISTED MOBILITY



REX
BIONICS

.....Addressing Diverse User Goals

Back To Work

"In my role as an engineer being able to stand and work is very important."

Jarard, 33 T-4 Complete Spinal Cord Injury



Eye To Eye

"You just have this feeling of finally seeing things from the right perspective again."

Irving, 56, C6 Complete Spinal Cord Injury



Feeling Good

"I see my time in REX P as what I call 'Rexercice', helping to keep my body well so that I don't suffer with the many secondary complications of my paralysis"

Sophie Morgan, 30, T-4 Complete Spinal Cord Injury



Courts now recognising the Benefits

Two Legal Cases Awarded insurance funding for REX robotic walking device

Rex Personal

“First British recipient of a High Court damages settlement to pay for a REX”



Robot-assisted Physiotherapy

“British Man awarded interim funding for an intensive course of robot-assisted physiotherapy with REX”

Distributors with Industry Relationships and Reputation

Country/Specialism

- United States Neuro-rehab
- China Pharma in China
- Hong Kong Neuro-rehab
- Benelux Neuro-rehab
- Belgium Robotics
- UK and A-NZ Direct

Other Priorities

- Japan
- Germany
- Other EU
- SE Asia

Portfolio of Ri Medical: US Partner



...supported by strong Marketing Programs and PR

THE TIMES

Spinal column Melanie Reid

'Now I'm upright. It feels peculiar, but also weirdly normal, towering over everyone like I used to do'

Melanie Reid broke her neck and back falling from a horse in April 2005. She spent 12 months in rehab and is now wheelchair-bound



It's come to this. A reminder of what I can do. I'm wearing my 'Wrong Trousers' trousers and I'm standing. It feels peculiar, but also weirdly normal, towering over everyone like I used to do.

The Daily Telegraph

Business: Tech inspiration, advice and news for entrepreneurs

'Wrong Trousers' take giant stride to global footprint for UK inventor

By Denise Roland



It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland

It's a small, unassuming device that has attracted the attention of US rehabilitation centres and healthcare insurers, writes Denise Roland



The robotic skeleton that helped Sophie to walk

7:42 - 20 MAY 2014



London Evening Standard

London Life

I, robot

PEOPLE

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

A high-tech exoskeleton is helping Sophie Morgan to walk again after 10 years in a wheelchair. The 30-year-old Sophie Morgan is the first person in the world to use the device

- Significant media interest in demonstrations
- Distribution partners leveraging the visibility
- Personal Injury Claims
- Global medical conferences
- Reference centers
- Clinical trials
- US phased launch in 2015-16

.....and Key Upcoming Target Milestones.....

- ☐ CE Mark ; FDA Class 1; qualified plant; *Soft Launch* ✓
- ☐ RAPPER II – first patient recruited ✓
- ☐ First REX awarded in Personal Injury claim ✓
- ☐ RAPPER II – initial data presentation ✓
- ☐ US phased Launch 2016
- ☐ Stroke Trial – first patient recruited (data in 2016/17) Q2-2016
- ☐ First patient in US Trial for REX P for Home Use Q2-2016
- ☐ RAPPER II – final data with clinical end-points and first publication Q4-2016
- ☐ First REX awarded in U.S. personal injury claim tba
- ☐ China launch Q2-2017
- ☐ FDA approval for home use Q3-2017

Financial Summary

- Rex financial year-end is 31 March
- Total of ~\$16m net of expenses raised in IPO on London AIM market May 2014 and secondary offering June 2015
- Cash of ~\$5.5m at 30 September 2015, no debt
- Average net monthly cash burn for 6 months to 30 September 2015 ~\$650k (excluding proceeds of June 2015 fundraising)
- 3 REX units sold in 6 months to 30 September 2015
- Unit sales expected to be higher in H2 2015/16 (some orders already in hand)

GBP1 = \$1.5

Why Rex ? Why Now ?

- Novel commercial stage product in growing field of Neuro-Rehabilitation (ageing population)
- Strong clinical data in post-marketing clinical evaluation
- Addresses substantial poorly-met healthcare need for mobility-challenged patients in multiple indications, including Spinal Cord Injury and Stroke
- Health benefits to Patient and Medical Professional; Economic benefits to provider and payer
- Unique “Hands free” feature
- CEO with proven track record of increasing shareholder value
- 2016 milestones
- Undervalued

Our Model: Intuitive Surgical & Robot-Assisted Surgery



Thank You

REX
BIONICS

“Robotic suit lets man paralysed by lorry in tragic London cycling accident surprise his daughter and stunned wedding guests” Evening Standard 22 September 2014



“Paralysed rugby player uses robot skeleton controlled by his THOUGHTS to walk again” MailOnline July 2015

